机构

• 上海药物研究所 [162]
• 西北高原生物研究所 [36]
• 近代物理研究所 [17]
• 昆明植物研究所 [6]
• 成都山地灾害与环境研... [4]
• 理论物理研究所 [4]
• 更多

采集方式

• OAI收割 [298]
• iSwitch采集 [9]

内容类型

• 期刊论文 [304]
• 会议论文 [3]

发表日期

• 2024 [8]
• 2023 [8]
• 2022 [10]
• 2021 [27]
• 2020 [10]
• 2019 [22]
• 更多

学科主题

• Physics [8]
• Pharmacolo... [5]
• Biochemist... [2]
• Chemistry [2]
• Chemistry,... [2]
• Multidisci... [2]
• 更多

筛选

浏览/检索结果: 共307条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Design, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-c] pyridine derivatives as p21-activated kinase 4 inhibitors for treatment of pancreatic cancer 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2025, 卷号: 15, 期号: 1, 页码: 438-466 作者:  Li, Yang;  Fang, Yan;  Chen, Xiaoyu;  Tong, Linjiang;  Feng, Fang   |  收藏  |  浏览/下载：10/0  |  提交时间：2025/04/01 P21-activated kinase 4  Tetrahydrobenzofuro[2  3-c]pyridine  Structure-activity relationship  Allosteric inhibitor  Pharmacokinetics properties  Kinase selectivity  Pancreatic cancer  Immune infiltration   Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2024, 页码: 21 作者:  Wang, Chaofan;  Fang, Yan;  Zhou, Ziqin;  Liu, Zhuoheng;  Feng, Fang   |  收藏  |  浏览/下载：10/0  |  提交时间：2024/09/26 Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 卷号: 9, 期号: 1, 页码: 17 作者:  Zhang, Tao;  Pan, Zilu;  Gao, Jing;  Wu, Qingqing;  Bai, Gang   |  收藏  |  浏览/下载：16/0  |  提交时间：2024/10/21 Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2024, 页码: 36 作者:  Lou, Jianfeng;  Zhou, Qianqian;  Lyu, Xilin;  Cen, Xinyi;  Liu, Chen   |  收藏  |  浏览/下载：5/0  |  提交时间：2024/08/22 GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2024, 页码: 11 作者:  He, Xiang;  Lu, Jiang-ling;  Liao, Wen-feng;  Long, Yi-ru;  Zhang, Xing   |  收藏  |  浏览/下载：7/0  |  提交时间：2024/08/20 cancer vaccine  adjuvant  granola frondose polysaccharide  GFPBW1  beta-glucan   Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2024, 页码: 11 作者:  Song, Pei-ran;  Wan, Zhi-peng;  Huang, Ge-ge;  Song, Zi-lan;  Zhang, Tao   |  收藏  |  浏览/下载：66/0  |  提交时间：2024/07/12 diffuse large B-cell lymphoma  BTK inhibitors  drug resistance  BTK C481F  BTK A428D  SYHA1813   A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease 期刊论文  OAI收割 MOLECULES, 2024, 卷号: 29, 期号: 8, 页码: 17 作者:  Huang, Yuqing;  Ning, Yi;  Chen, Zhiwei;  Song, Peiran;  Tang, Haotian   |  收藏  |  浏览/下载：14/0  |  提交时间：2024/05/31 IRAK4 inhibitor  peritonitis  inflammatory bowel disease (IBD)  macrophage   Introduction and Safe Use of Gas Cylinders in China 期刊论文  OAI收割 ACS Sustainable Chem. Eng., 2024, 卷号: 2024, 期号: 12, 页码: 5496−5508 作者:  Ming-Ming Yu;  Zhenghao hang Zhang;  Gui-Ling Guan;  Bhagyesha Patil;  Priya Darshini Srinivasan   |  收藏  |  浏览/下载：12/0  |  提交时间：2024/12/23 carbon dioxide  doping  Co-based catalysts  hydrogenation  reaction mechanisms   A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy 期刊论文  OAI收割 CANCER COMMUNICATIONS, 2024, 页码: 5 作者:  Liu, Yingqiang;  Tong, Linjiang;  Zhang, Mengge;  Zhang, Qi;  Liu, Qiupei   |  收藏  |  浏览/下载：37/0  |  提交时间：2024/03/13 From bench to bedside: current development and emerging trend of KRAS-targeted therapy 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2023, 页码: 18 作者:  Chen, Yi;  Liu, Qiu-pei;  Xie, Hua;  Ding, Jian   |  收藏  |  浏览/下载：54/0  |  提交时间：2024/01/16 KRAS mutation  KRAS(G12C) inhibitor  Pan-KRAS inhibitor  SHP2 allosteric inhibitor  SOS1 inhibitor  combination therapy